Over the past decade, FDA has begun to approve limited controlled studies to explore the therapeutic potentials of psychedelic medicines. Two of the most promising and popular study subjects are MDMA & Psilocybin. As hopeful results begin to emerge through multiple phase II and phase III studies, the field of psychiatry is beginning to experience a long-due and promising renaissance in care.
Nature Research Journal recently published an in-depth report of how MDMA (ecstasy) and psilocybin are offering groundbreaking promise in the treatment of varying depressive and anxiety disorders, as well as the findings across various research trials.
"Psychedelic-assisted psychotherapy could provide needed options for debilitating mental-health disorders including PTSD, major depressive disorder, alcohol-use disorder, anorexia nervosa and more that kill thousands every year in the United States, and cost billions worldwide in lost productivity."
"Several trials show dramatic results: in a study published in November 2020, for example, 71% of people who took psilocybin for major depressive disorder showed a greater than 50% reduction in symptoms after four weeks, and half of the participants entered remission1. Some follow-up studies after therapy, although small, have shown lasting benefits."
